Arvinas, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for ARVN, updated each market day.
ARVN AI Sentiment
AI predicts Arvinas, Inc stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Sector
Exchange
Market Cap
$714,444,336
Cap Tier
Employees
246
Headquarters
NEW HAVEN, CT
Listed Since
Sept. 27, 2018
Website
ARVN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ARVN Volatility
Arvinas, Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
